Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients

Phase II Study of Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients

This study is to explore the clinical efficacy of continuous Endostar infusion combined with radiotherapy in esophageal cancer patients.

Inclusion Criteria:

• Histological or cytological diagnosis of previously untreated stage I-III esophageal cancer
• Measurable disease according to RECIST criteria
• ECOG Performance Status 0-1
• The length of esophageal carcinoma ≤ 10 cm
• Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 90g/L
• Renal function: Cr ≤ 2.0×UNL
• Hepatic function: BIL ≤ 2.0×UNL, ALT/AST ≤ 5.0×UNL

Exclusion Criteria:

• Pregnant or lactating women
• Evidence of bleeding diathesis, serious infection
• Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension)
• Uncontrollable mental and nervous disorders